Under the agreement, the two companies will work to develop affinity-based products for use in the production processes for protein-based pharmaceuticals. The development of these products will be based on Affibodies™, a novel class of small, robust affinity proteins designed to bind desired protein targets. Financial details of the agreement were not disclosed.
“The use of Affibodies™ opens up new possibilities for large-scale protein purification for production of protein based pharmaceuticals. We are very pleased that we can continue to build value through our successful collaboration with Affibody”, said Peter Ehrenheim, Vice President of Protein Separations at Amersham Biosciences.
Affibody and Amersham Biosciences have a successful ongoing collaboration, which was initiated two years ago. For Amersham Biosciences, the newly initiated collaboration entails an expansion of the Company’s research portfolio regarding products for purification, i.e. affinity chromatography.
“The agreement validates the commercial value of Affibody’s technology and is an important milestone for us. This also shows that Affibody is an attractive business partner. Our collaboration with Amersham Biosciences has been very fruitful so far, and has already resulted in royalty revenues,” says Torben Jørgensen, CEO of Affibody.
Torben Jørgensen | Source: alphagalileo
Further information: www.affibody.com
More articles from Life Sciences:
Genome sequence for the domestic horse to be unveiled
06.11.2009 | University of California - Davis
Common plants can eliminate indoor air pollutants
06.11.2009 | American Society for Horticultural Science
Airborne nitrogen shifts aquatic nutrient limitation in pristine lakes
06.11.2009 | Studies and Analyses
Genome sequence for the domestic horse to be unveiled
06.11.2009 | Life Sciences
06.11.2009 | Earth Sciences
Texas Tech University Hosts Major Textile Conference in India
06.11.2009 | Event News
Brief Highlights of the Fluid Dynamics Conference, Minneapolis
30.10.2009 | Event News
EUROSAFE Forum 2009 Brussels: "Safety Implications of an Increased Demand for Nuclear Energy"
29.10.2009 | Event News